HALOZYME THERAPEUTICS INC (HALO) Stock Fundamental Analysis

NASDAQ:HALO • US40637H1095

71.66 USD
-1.57 (-2.14%)
Last: Feb 19, 2026, 01:05 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

Overall HALO gets a fundamental rating of 6 out of 10. We evaluated HALO against 521 industry peers in the Biotechnology industry. While HALO belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. HALO has a bad growth rate and is valued cheaply. These ratings would make HALO suitable for value investing!


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • HALO had positive earnings in the past year.
  • HALO had a positive operating cash flow in the past year.
  • Of the past 5 years HALO 4 years were profitable.
  • Of the past 5 years HALO 4 years had a positive operating cash flow.
HALO Yearly Net Income VS EBIT VS OCF VS FCFHALO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

  • With an excellent Return On Assets value of 26.81%, HALO belongs to the best of the industry, outperforming 97.50% of the companies in the same industry.
  • With an excellent Return On Equity value of 118.17%, HALO belongs to the best of the industry, outperforming 99.62% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 42.77%, HALO belongs to the top of the industry, outperforming 99.23% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for HALO is in line with the industry average of 18.69%.
  • The last Return On Invested Capital (42.77%) for HALO is above the 3 year average (17.81%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 26.81%
ROE 118.17%
ROIC 42.77%
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
HALO Yearly ROA, ROE, ROICHALO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 200 300

1.3 Margins

  • Looking at the Profit Margin, with a value of 47.91%, HALO belongs to the top of the industry, outperforming 98.27% of the companies in the same industry.
  • HALO's Profit Margin has declined in the last couple of years.
  • HALO has a better Operating Margin (59.33%) than 100.00% of its industry peers.
  • HALO's Operating Margin has declined in the last couple of years.
  • HALO's Gross Margin of 84.55% is amongst the best of the industry. HALO outperforms 87.33% of its industry peers.
  • HALO's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 59.33%
PM (TTM) 47.91%
GM 84.55%
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
HALO Yearly Profit, Operating, Gross MarginsHALO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so HALO is creating value.
  • HALO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
HALO Yearly Shares OutstandingHALO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
HALO Yearly Total Debt VS Total AssetsHALO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

  • An Altman-Z score of 5.25 indicates that HALO is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of HALO (5.25) is better than 73.51% of its industry peers.
  • HALO has a debt to FCF ratio of 2.51. This is a good value and a sign of high solvency as HALO would need 2.51 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 2.51, HALO belongs to the best of the industry, outperforming 92.71% of the companies in the same industry.
  • A Debt/Equity ratio of 1.59 is on the high side and indicates that HALO has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 1.59, HALO is doing worse than 76.78% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.59
Debt/FCF 2.51
Altman-Z 5.25
ROIC/WACC5.43
WACC7.87%
HALO Yearly LT Debt VS Equity VS FCFHALO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

  • HALO has a Current Ratio of 1.59. This is a normal value and indicates that HALO is financially healthy and should not expect problems in meeting its short term obligations.
  • HALO's Current ratio of 1.59 is on the low side compared to the rest of the industry. HALO is outperformed by 79.65% of its industry peers.
  • HALO has a Quick Ratio of 1.37. This is a normal value and indicates that HALO is financially healthy and should not expect problems in meeting its short term obligations.
  • HALO has a Quick ratio of 1.37. This is amonst the worse of the industry: HALO underperforms 80.81% of its industry peers.
Industry RankSector Rank
Current Ratio 1.59
Quick Ratio 1.37
HALO Yearly Current Assets VS Current LiabilitesHALO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • HALO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.36%.
  • Measured over the past years, HALO shows a very strong growth in Earnings Per Share. The EPS has been growing by 35.63% on average per year.
EPS 1Y (TTM)-2.36%
EPS 3Y22.99%
EPS 5Y35.63%
EPS Q2Q%-119.05%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%51.6%

3.2 Future

  • The Earnings Per Share is expected to grow by 17.28% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 5.67% on average over the next years.
EPS Next Y101.78%
EPS Next 2Y54.48%
EPS Next 3Y35.8%
EPS Next 5Y17.28%
Revenue Next Year26.89%
Revenue Next 2Y19.59%
Revenue Next 3Y12.37%
Revenue Next 5Y5.67%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
HALO Yearly Revenue VS EstimatesHALO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
HALO Yearly EPS VS EstimatesHALO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

9

4. Valuation

4.1 Price/Earnings Ratio

  • HALO is valuated rather expensively with a Price/Earnings ratio of 17.35.
  • Based on the Price/Earnings ratio, HALO is valued cheaper than 95.59% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.27. HALO is valued slightly cheaper when compared to this.
  • HALO is valuated reasonably with a Price/Forward Earnings ratio of 8.60.
  • 98.27% of the companies in the same industry are more expensive than HALO, based on the Price/Forward Earnings ratio.
  • HALO's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.16.
Industry RankSector Rank
PE 17.35
Fwd PE 8.6
HALO Price Earnings VS Forward Price EarningsHALO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HALO indicates a rather cheap valuation: HALO is cheaper than 96.74% of the companies listed in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of HALO indicates a rather cheap valuation: HALO is cheaper than 97.12% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 13.99
EV/EBITDA 11.16
HALO Per share dataHALO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8 10

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The excellent profitability rating of HALO may justify a higher PE ratio.
  • A more expensive valuation may be justified as HALO's earnings are expected to grow with 35.80% in the coming years.
PEG (NY)0.17
PEG (5Y)0.49
EPS Next 2Y54.48%
EPS Next 3Y35.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • HALO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HALOZYME THERAPEUTICS INC

NASDAQ:HALO (2/19/2026, 1:05:52 PM)

71.66

-1.57 (-2.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-17
Earnings (Next)05-04
Inst Owners105.85%
Inst Owner Change-18.42%
Ins Owners0.81%
Ins Owner Change-0.62%
Market Cap8.43B
Revenue(TTM)N/A
Net Income(TTM)595.49M
Analysts76
Price Target79.56 (11.02%)
Short Float %11.63%
Short Ratio6.63
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.41%
Min EPS beat(2)3.56%
Max EPS beat(2)19.26%
EPS beat(4)4
Avg EPS beat(4)11.06%
Min EPS beat(4)3.56%
Max EPS beat(4)19.26%
EPS beat(8)7
Avg EPS beat(8)12.2%
EPS beat(12)10
Avg EPS beat(12)9.54%
EPS beat(16)13
Avg EPS beat(16)9.68%
Revenue beat(2)2
Avg Revenue beat(2)6.93%
Min Revenue beat(2)2.18%
Max Revenue beat(2)11.69%
Revenue beat(4)4
Avg Revenue beat(4)7.01%
Min Revenue beat(4)1.36%
Max Revenue beat(4)12.81%
Revenue beat(8)6
Avg Revenue beat(8)5.71%
Revenue beat(12)7
Avg Revenue beat(12)2.94%
Revenue beat(16)9
Avg Revenue beat(16)2.47%
PT rev (1m)2.63%
PT rev (3m)3.08%
EPS NQ rev (1m)15.2%
EPS NQ rev (3m)13.89%
EPS NY rev (1m)4.46%
EPS NY rev (3m)6.45%
Revenue NQ rev (1m)11.18%
Revenue NQ rev (3m)11.2%
Revenue NY rev (1m)3.44%
Revenue NY rev (3m)5.06%
Valuation
Industry RankSector Rank
PE 17.35
Fwd PE 8.6
P/S 6.78
P/FCF 13.99
P/OCF 13.79
P/B 16.72
P/tB N/A
EV/EBITDA 11.16
EPS(TTM)4.13
EY5.76%
EPS(NY)8.33
Fwd EY11.63%
FCF(TTM)5.12
FCFY7.15%
OCF(TTM)5.2
OCFY7.25%
SpS10.57
BVpS4.28
TBVpS-2.22
PEG (NY)0.17
PEG (5Y)0.49
Graham Number19.95
Profitability
Industry RankSector Rank
ROA 26.81%
ROE 118.17%
ROCE 53.28%
ROIC 42.77%
ROICexc 86.79%
ROICexgc N/A
OM 59.33%
PM (TTM) 47.91%
GM 84.55%
FCFM 48.47%
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
ROICexc(3y)23.94%
ROICexc(5y)N/A
ROICexgc(3y)71.73%
ROICexgc(5y)N/A
ROCE(3y)22.19%
ROCE(5y)37.11%
ROICexgc growth 3Y-1.13%
ROICexgc growth 5YN/A
ROICexc growth 3Y-28.16%
ROICexc growth 5YN/A
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
F-Score8
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 1.59
Debt/FCF 2.51
Debt/EBITDA 0.98
Cap/Depr 10.51%
Cap/Sales 0.69%
Interest Coverage 250
Cash Conversion 74.59%
Profit Quality 101.16%
Current Ratio 1.59
Quick Ratio 1.37
Altman-Z 5.25
F-Score8
WACC7.87%
ROIC/WACC5.43
Cap/Depr(3y)13.62%
Cap/Depr(5y)33.32%
Cap/Sales(3y)1.21%
Cap/Sales(5y)0.98%
Profit Quality(3y)118.15%
Profit Quality(5y)93.9%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.36%
EPS 3Y22.99%
EPS 5Y35.63%
EPS Q2Q%-119.05%
EPS Next Y101.78%
EPS Next 2Y54.48%
EPS Next 3Y35.8%
EPS Next 5Y17.28%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%51.6%
Revenue Next Year26.89%
Revenue Next 2Y19.59%
Revenue Next 3Y12.37%
Revenue Next 5Y5.67%
EBIT growth 1Y54.59%
EBIT growth 3Y25.97%
EBIT growth 5YN/A
EBIT Next Year61.82%
EBIT Next 3Y38.38%
EBIT Next 5Y15.57%
FCF growth 1Y70.36%
FCF growth 3Y16.28%
FCF growth 5YN/A
OCF growth 1Y65.76%
OCF growth 3Y16.96%
OCF growth 5YN/A

HALOZYME THERAPEUTICS INC / HALO FAQ

Can you provide the ChartMill fundamental rating for HALOZYME THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 6 / 10 to HALO.


Can you provide the valuation status for HALOZYME THERAPEUTICS INC?

ChartMill assigns a valuation rating of 9 / 10 to HALOZYME THERAPEUTICS INC (HALO). This can be considered as Undervalued.


Can you provide the profitability details for HALOZYME THERAPEUTICS INC?

HALOZYME THERAPEUTICS INC (HALO) has a profitability rating of 8 / 10.


What is the financial health of HALOZYME THERAPEUTICS INC (HALO) stock?

The financial health rating of HALOZYME THERAPEUTICS INC (HALO) is 5 / 10.


Can you provide the expected EPS growth for HALO stock?

The Earnings per Share (EPS) of HALOZYME THERAPEUTICS INC (HALO) is expected to grow by 101.78% in the next year.